Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
68.63
-3.27 (-4.55%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Employees
Spyre Therapeutics had 102 employees as of December 31, 2025. The number of employees increased by 37 or 56.92% compared to the previous year.
Employees
102
Change (1Y)
37
Growth (1Y)
56.92%
Revenue / Employee
n/a
Profits / Employee
-$1,240,608
Market Cap
5.92B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Rhythm Pharmaceuticals | 414 |
| Immunovant | 362 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
| Celcuity | 155 |
| CG Oncology | 142 |
| Protagonist Therapeutics | 132 |
SYRE News
- 12 days ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million - GlobeNewsWire
- 14 days ago - Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock - GlobeNewsWire
- 15 days ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - GlobeNewsWire
- 15 days ago - Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug - Benzinga
- 16 days ago - Spyre Therapeutics Transcript: Study result - Transcripts
- 16 days ago - Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - GlobeNewsWire
- 18 days ago - Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 - GlobeNewsWire
- 25 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire